Biovica International
14.9.2021 08:21:37 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 14, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen the potential of DiviTum ® TKa as a treatment monitoring devise for CDK4/6 inhibitor treatments.
The results from a large independent study with a CDK4/6 inhibitor therapy and DiviTum ® TKa as a treatment monitoring assay in 287 patients with metastatic breast cancer is presented at the ESMO congress.
"I'm happy to see that the presented results on this CDK4/6 inhibitor ribociclib are consistent with earlier CDK4/6-results for example for palbociclib. The study results are highly encouraging as a reference for using DiviTum®TKa for the monitoring of CDK4/6 inhibitor treatments in HR positive metastatic breast cancer," said Anders Rylander, CEO of Biovica.
The study concludes that TKa appears to be a new promising prognostic, predictive and monitoring biomarker in patients with HR positive/HER2 negative metastatic breast cancer treated with ribociclib plus letrozole as first-line therapy. Baseline and dynamic TKa changes provided independent valuable information. Lack of TKa suppression at day 15 indicates enrichment for primary resistance and poor prognosis. TKa rebound at treatment cycle 2, day 1 may indicate early adaptation to ribociclib plus letrozole, while persistent suppression seems to identify patients with sustained inhibition and excellent prognosis.
Link to poster: https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=292P+-+
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum ® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
Attachments
Promising DiviTumTKa results from BioItaLEE study presented at ESMO
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/663954/Promising-DiviTumTKa-Results-from-BioItaLEE-Study-Presented-at-ESMO
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GTDC Research Details Distribution's Influence on AI, Cloud and Hyperscaler Sales and Adoption3.3.2026 16:00:00 CET | Press release
IT distributors have become digital ecosystem orchestrators that unify cloud, AI, hyperscaler, and subscription-based business models. Distribution significantly accelerates vendor growth while reducing risk, allowing suppliers to scale efficiently, expand partner bases, enter new markets and mitigate financial and operational liabilities. Digital platforms are creating a new GTM "operating system". These systems offer end-to-end digital commerce and intelligence layers to manage procurement, billing, lifecycles and analytics. TAMPA, FL / ACCESS Newswire / March 3, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, has released a new research report, Distribution: The Digital Force Multiplier. Developed by CommCentric Solutions, this study examines how IT distribution has transformed and continues to evolve into a critical enabler of cloud, artificial intelligence (AI), hyperscaler and platform-driven business models acr
Datavault AI Reports Significant Institutional Ownership Growth as Platform Expansion Accelerates3.3.2026 14:08:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / March 3, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, today highlighted a marked increase in institutional ownership alongside continued commercial expansion across media and enterprise markets. Between the fourth quarter of 2025 and February 2026, several major asset managers significantly expanded their positions in Datavault AI. According to recent public filings, Vanguard increased its holdings from approximately 393,000 shares to 11.8 million shares. State Street expanded from roughly 335,000 shares to 10.0 million shares. BlackRock increased its position from approximately 136,000 shares to 4.1 million shares. These changes represent percentage increases of approximately 2,900%, 2,800%, and 3,000%, respectively. Management views this increase in institutional participation as support for Datavault AI'
AccessPay Partners With PayPoint to Strengthen Fraud and Error Prevention for Corporate Payments3.3.2026 10:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / March 3, 2026 / AccessPay, the leading bank integration provider, today announced a new partnership with PayPoint to integrate PayPoint's Confirmation of Payee (CoP) capability into AccessPay's payments automation suite for modern finance teams. With £258m lost to authorised push payment (APP) fraud in the first half of 2025 alone, organisations need access to robust payment controls that scale with their operations.1 PayPoint's CoP offering enables AccessPay's customers to verify payee account details as part of their payment workflows, reinforcing AccessPay's position at the centre of a growing ecosystem of technologies designed to automate and de-risk the Office of the CFO. CoP, also known as Account Name Verification (ANV), is a valuable anti-fraud measure that checks the accuracy of payee details before funds are sent. It can be used to confirm payee details at the point of collection, when creating a payment instruction, or both. PayPoint's CoP
Affiliate of Pacific Avenue Capital Partners to Acquire Care.com from IAC3.3.2026 01:00:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / March 2, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has entered into an agreement to acquire Care.com from IAC Inc. (NASDAQ:IAC). Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S. Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in
Stagwell Launches Stagwell Search+: The Industry's First Agentic Platform To Win AI Search2.3.2026 14:30:00 CET | Press release
New media solution enables brands to win discoverability, visibility, positive sentiment, and outcomes across major AI systems NEW YORK, NY AND LONDON, UK / ACCESS Newswire / March 2, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the global launch of Stagwell Search+, the industry's first agentic platform for AI Search experiences. Built by Assembly, Stagwell's global omnichannel media agency, in partnership with Emberos, the operating system for AI visibility, Stagwell Search+ is a category-defining solution to master the transition from traditional search engines to AI search experiences. As Large Language Models (LLMs) increasingly mediate how people discover, compare, and choose, Stagwell Search+ helps brands optimize not just for clicks and traffic, but for a new era of search where AI guides decisions and the goal is to be chosen. The solution combines an agentic platform with a differentiated framework that improv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom